Keywords: b-ms, flamel, basulin, licensing, deal, worthup, million
B-MS and Flamel in Basulin licensing deal worthup to $165 million
Article | 08 September 2003
US firm Bristol-Myers Squibb and Flamel Technologies have entered into a licensing and commercialization agreement to develop and market Basulin, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
